The Phase 3 study of the drug Vandetanib, marketed by London company AstraZeneca PLC has begun.
The study will cover 508 patients of lung cancer in whom the first-line treatment has failed. The study extends over 20 countries and 20 sites.
The patients who have a recorded a case of locally advanced or metastatic non-small cell lung cancer will be given the once-daily drug Vandetanib in addition to pemetrexed, as a second line treatment.
Says Medical Science Director for Vandetanib, Dr Peter Langmuir, 'After treatment failure with initial therapy, response rates to further treatment are low in patients with advanced non-small cell lung cancer.
'The effect of combining novel targeted agents, such as Vandetanib, with chemotherapy needs to be explored in order to further progress treatment options for patient benefit.'
The study will mainly focus on progression-free survival rates of the subjects.